To explore the effect of immune checkpoints on tumor regression, Yu and Jang [21] examined mathematical models of tumor-immune interactions among CD4+ T cells, malignant tumor cells, and antitumor cytokine with an immune checkpoint inhibitor of CTLA-4. Here, CTLA4 is linked to neoplasm.